Minnesota is currently home to 2064 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I
Recruiting
A first-in-human study using ISP-001 in adult patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Mucopolysaccharidosis IH/S, Mucopolysaccharidosis IS
Study of RYZ101 in Combination with SoC in Subjects with SSTR+ ES-SCLC
Recruiting
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Research Facility, Rochester, Minnesota
Conditions: SCLC,Extensive Stage
Acute Recording of Stereotyped High-Frequency Oscillations
Recruiting
Overall, this study will investigate the functional utility of stereotyped HFOs by capturing them with a new implantable system (Brain Interchange - BIC of CorTec), which can sample neural data at higher rates \>=1kHz and deliver targeted electrical stimulation to achieve seizure control. In contrast to current closed-loop systems (RNS), which wait for the seizure to start before delivering stimulation, the BIC system will monitor the spatial topography and rate of stereotyped HFOs and deliver t... Read More
Gender:
ALL
Ages:
Between 3 years and 70 years
Trial Updated:
03/20/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Epilepsy
Investigate Efficacy and Safety of Carisbamate As Adjunctive Treatment for Seizures Associated with LGS in Children and Adults
Recruiting
The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).
Gender:
ALL
Ages:
Between 4 years and 55 years
Trial Updated:
03/20/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Seizures, Lennox Gastaut Syndrome
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/20/2025
Locations: Mayo Clinic - Rochester, Rochester, Minnesota
Conditions: Partial Epilepsy
Cephea Early Feasibility Study
Recruiting
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Minneapolis Heart Institute, Minneapolis, Minnesota
Conditions: Mitral Regurgitation
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Recruiting
Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesenchymal origin, notably sarcoma and mesothelioma, FAP expression has also been observed on the tumor cells themselves. Given the restricted expression profile, FAP is a promising target for peptide-target... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Solid Tumor
Study to Evaluate VT3989 in Patients with Metastatic Solid Tumors
Recruiting
This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in 3- or 4-week cycles in patients with mesothelioma and/or metastatic solid tumors that are resistant or refractory to standard therapy or for which no effective standard therapy is available.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota
Conditions: Solid Tumor, Adult, Mesothelioma, NSCLC
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/20/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: NASH - Nonalcoholic Steatohepatitis
MitraClip REPAIR MR Study
Recruiting
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Abbott Northwestern Hospital, Minneapolis, Minnesota
Conditions: Mitral Valve Regurgitation
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Recruiting
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Non-Small Cell Lung Cancer
Dynamics of Organ Damage and Immune Exhaustion During Sepsis
Recruiting
This is a prospective, non-randomized study investigating if organ damage and immune changes can be measured by liquid biopsy NGS through advanced analytical methods.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Sepsis